BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30746541)

  • 1. In-flow photooxygenation of aminothienopyridinones generates iminopyridinedione PTP4A3 phosphatase inhibitors.
    Tasker NR; Rastelli EJ; Blanco IK; Burnett JC; Sharlow ER; Lazo JS; Wipf P
    Org Biomol Chem; 2019 Feb; 17(9):2448-2466. PubMed ID: 30746541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor.
    Salamoun JM; McQueeney KE; Patil K; Geib SJ; Sharlow ER; Lazo JS; Wipf P
    Org Biomol Chem; 2016 Jul; 14(27):6398-402. PubMed ID: 27291491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Cell-Active Inhibitors of the Undrugged Oncogenic PTP4A3 Phosphatase.
    Lazo JS; Blanco IK; Tasker NR; Rastelli EJ; Burnett JC; Garrott SR; Hart DJ; McCloud RL; Hsu KL; Wipf P; Sharlow ER
    J Pharmacol Exp Ther; 2019 Dec; 371(3):652-662. PubMed ID: 31601683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of bifunctional PTP4A3 phosphatase inhibitors activating the ER stress pathway.
    Rastelli EJ; Sannino S; Hart DJ; Sharlow ER; Lazo JS; Brodsky JL; Wipf P
    Bioorg Med Chem Lett; 2021 Aug; 46():128167. PubMed ID: 34089839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of the Complex of an Iminopyridinedione Protein Tyrosine Phosphatase 4A3 Phosphatase Inhibitor with Human Serum Albumin.
    Czub MP; Boulton AM; Rastelli EJ; Tasker NR; Maskrey TS; Blanco IK; McQueeney KE; Bushweller JH; Minor W; Wipf P; Sharlow ER; Lazo JS
    Mol Pharmacol; 2020 Dec; 98(6):648-657. PubMed ID: 32978326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational inhibitors of PTP4A3 phosphatase as antineoplastic agents.
    Sharlow ER; Wipf P; McQueeney KE; Bakan A; Lazo JS
    Expert Opin Investig Drugs; 2014 May; 23(5):661-73. PubMed ID: 24625356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors.
    Tasker NR; Rastelli EJ; Burnett JC; Sharlow ER; Lazo JS; Wipf P
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2008-2015. PubMed ID: 31307888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A chemical genetics approach identifies PTP4A3 as a regulator of colon cancer cell adhesion.
    McQueeney KE; Salamoun JM; Ahn JG; Pekic P; Blanco IK; Struckman HL; Sharlow ER; Wipf P; Lazo JS
    FASEB J; 2018 Oct; 32(10):5661-5673. PubMed ID: 29746167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Credentialing and Pharmacologically Targeting PTP4A3 Phosphatase as a Molecular Target for Ovarian Cancer.
    Lazo JS; Sharlow ER; Cornelison R; Hart DJ; Llaneza DC; Mendelson AJ; Rastelli EJ; Tasker NR; Landen CN; Wipf P
    Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34209460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fullerene derivatives as a new class of inhibitors of protein tyrosine phosphatases.
    Kobzar OL; Trush VV; Tanchuk VY; Zhilenkov AV; Troshin PA; Vovk AI
    Bioorg Med Chem Lett; 2014 Jul; 24(14):3175-9. PubMed ID: 24856066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells.
    Min G; Lee SK; Kim HN; Han YM; Lee RH; Jeong DG; Han DC; Kwon BM
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3769-74. PubMed ID: 23726031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.
    Taha MO; Bustanji Y; Al-Bakri AG; Yousef AM; Zalloum WA; Al-Masri IM; Atallah N
    J Mol Graph Model; 2007 Mar; 25(6):870-84. PubMed ID: 17035054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,2,3,4-Tetrahydroisoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors.
    Klopfenstein SR; Evdokimov AG; Colson AO; Fairweather NT; Neuman JJ; Maier MB; Gray JL; Gerwe GS; Stake GE; Howard BW; Farmer JA; Pokross ME; Downs TR; Kasibhatla B; Peters KG
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1574-8. PubMed ID: 16386905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2-Oxo-1,2-dihydropyridinyl-3-yl amide-based GPa inhibitors: Design, synthesis and structure-activity relationship study.
    Loughlin WA; Jenkins ID; Karis ND; Schweiker SS; Healy PC
    Eur J Med Chem; 2016 Mar; 111():1-14. PubMed ID: 26851835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase.
    Maccari R; Ottanà R; Ciurleo R; Paoli P; Manao G; Camici G; Laggner C; Langer T
    ChemMedChem; 2009 Jun; 4(6):957-62. PubMed ID: 19288492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monocyclic thiophenes as protein tyrosine phosphatase 1B inhibitors: capturing interactions with Asp48.
    Wan ZK; Lee J; Xu W; Erbe DV; Joseph-McCarthy D; Follows BC; Zhang YL
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4941-5. PubMed ID: 16806920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Site-specific incorporation of allosteric-inhibition sites in a protein tyrosine phosphatase.
    Zhang XY; Bishop AC
    J Am Chem Soc; 2007 Apr; 129(13):3812-3. PubMed ID: 17346049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of thiazolidinones spiro-fused to indolin-2-ones as potent and selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase B.
    Vintonyak VV; Warburg K; Kruse H; Grimme S; Hübel K; Rauh D; Waldmann H
    Angew Chem Int Ed Engl; 2010 Aug; 49(34):5902-5. PubMed ID: 20632348
    [No Abstract]   [Full Text] [Related]  

  • 19. Structure-based virtual screening approach to the discovery of novel inhibitors of eyes absent 2 phosphatase with various metal chelating moieties.
    Park H; Jung SK; Yu KR; Kim JH; Kim YS; Ko JH; Park BC; Kim SJ
    Chem Biol Drug Des; 2011 Oct; 78(4):642-50. PubMed ID: 21777393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
    Rivas DR; Dela Cerna MVC; Smith CN; Sampathi S; Patty BG; Lee D; Blackburn JS
    Sci Rep; 2021 May; 11(1):10302. PubMed ID: 33986418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.